About the Parkinson's disease blog

The Parkinson's disease blog is an independent publication launched in June 2024 by Right Brain Bio, Inc. with content provided by its CEO & Founder, Jonathan Sackner-Bernstein, MD.

By subscribing, you'll get full access to the website as well as email newsletters about new content when it's available. Your subscription motivates us to keep this blog active and responsive to feedback. Please share with others. Thank you!

Who is Jonathan Sackner-Bernstein, MD?

Dr. Sackner-Bernstein studied engineering prior to his career as a physician. He served on the faculty of Columbia University while focused on clinical care and clinical trials focused on heart failure. His expertise in drug development is based on expertise built in industry, at the FDA and with DARPA. And Sackner-Bernstein's mission of conquering Parkinson's started as his buddy and mentor began to suffer from worsening Parkinson's disease. Read more on LinkedIn, Wikipedia or by googling him.

What the blog is not...

Despite writing about ways we believe could help or hurt people with Parkinson's, this is not a site to be used for your clinical decision making. It is not intended to provide medical guidance, rather, to provide scientific insights delivered for the lay public interested in Parkinson's disease. All clinical matters must be discussed with and overseen by your physician.

Our commitment

Starting as one person's hobby and now as a company focused on the development of dopamine reduction therapy for those with Parkinson's, we will share questions, ideas and possibilities. These posts will be based on science and/or reasoning, applying the author's (Jonathan Sackner-Bernstein) expertise as an engineer, clinician (cardiologist), clinical trialist, regulator and innovator.

Give us feedback

Have an idea or request? Please send it to us at news@rightbrainbio.com. We will read all emails but cannot promise to respond or integrate your ideas into the blog. And that is not because we don't value the input, but rather, because we need to keep our primary focus on the development of the medicine we believe to be transformative to so many lives.